Stifel Financial Corp Supernus Pharmaceuticals, Inc. Transaction History
Stifel Financial Corp
- $86.8 Billion
- Q2 2024
A detailed history of Stifel Financial Corp transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 68,041 shares of SUPN stock, worth $2.32 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,041
Previous 69,315
1.84%
Holding current value
$2.32 Million
Previous $2.36 Million
23.01%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding SUPN
# of Institutions
259Shares Held
59.3MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$355 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$210 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$180 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$97.9 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$91.5 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.83B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...